CHD8

Across TCGA pan-cancer cohorts, CHD8 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CHD8 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CHD8 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHD8 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where CHD8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.307	0.598	.007	18	view →
CCRCC	OS	Median	III,IV	0.426	0.932	.026	9	view →
GBM	DFS	Median	All	0.455	0.287	.016	4	view →
LUAD	DFS	Median	II,III,IV	0.945	0.768	.022	3	view →
LSCC	DFS	Tertile	II,III,IV	0.836	0.578	.038	3	view →
HNSC	OS	Median	All	0.625	0.787	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CHD8–PDAC (DFS)

Open the PDAC breakdown →